Abstract

This article describes Bacteria ID Chips (‘BacChips’): an inexpensive, portable, and autonomous microfluidic platform for identifying pathogenic strains of bacteria. BacChips consist of a set of microchambers and channels molded in the elastomeric polymer, poly(dimethylsiloxane) (PDMS). Each microchamber is preloaded with mono-, di-, or trisaccharides and dried. Pressing the layer of PDMS into contact with a glass coverslip forms the device; the footprint of the device in this article is ∼6 cm2. After assembly, BacChips are degased under large negative pressure and are stored in vacuum-sealed plastic bags. To use the device, the bag is opened, a sample containing bacteria is introduced at the inlet of the device, and the degased PDMS draws the sample into the central channel and chambers. After the liquid at the inlet is consumed, air is drawn into the BacChip via the inlet and provides a physical barrier that separates the liquid samples in adjacent microchambers. A pH indicator is admixed with the samples prior to their loading, enabling the metabolism of the dissolved saccharides in the microchambers to be visualized. Importantly, BacChips operate without external equipment or instruments. By visually detecting the growth of bacteria using ambient light after ∼4 h, we demonstrate that BacChips with ten microchambers containing different saccharides can reproducibly detect the ESKAPE panel of pathogens, including strains of: Enterococcus faecalis, Enteroccocus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes, and Enterobacter cloacae. This article describes a BacChip for point-of-care detection of ESKAPE pathogens and a starting point for designing multiplexed assays that identify bacterial strains from clinical samples and simultaneously determine their susceptibility to antibiotics.

Highlights

  • The ESKAPE acronym (Enterococcus faecium, Staphylococcus auerus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacter species) coined by Rice represents a collection of the most common nosocomial pathogens that escape the effects of many clinical antibiotics [1,2]

  • Bacterial Strains Strains used in this study–unless otherwise noted–were clinical isolates obtained from stocks cultured in the Department of Medical Microbiology and Immunology (MMI) at the University of Wisconsin–Madison, including: Enterococcus faecalis, Enterococcus faecium (A634; from Bernard Weisblum, Department of Pharmacology, University of Wisconsin–Madison), Staphylococcus aureus (ATCC 25923 and ATCC 13565; an FRI-100 isolate from the Food Research Institute, Madison, Wisconsin, USA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa (ATCC 14207), Enterobacter aerogenes (ATCC 13048), Enterobacter cloacae

  • We tested solutions of 10%, 25%, 50%, and 100% Luria Bertani (LB) in saline in combination with different cell loading concentrations of A. baumannii and determined their effect on the rate of the development of the unique pattern of colored microchambers that was characteristic for this organism

Read more

Summary

Introduction

The ESKAPE acronym (Enterococcus faecium, Staphylococcus auerus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacter species) coined by Rice represents a collection of the most common nosocomial pathogens that escape the effects of many clinical antibiotics [1,2]. There are two measurable factors that can guide the treatment of patients with bacterial infections. We recently demonstrated a portable, simple-to-use microfluidic device that enables the determination of MIC values for clinical pathogens [4]. The other factor is the identity of the pathogen Together, these two factors enable pathologists to prescribe antibiotics at doses that minimize the risk of bacteria developing resistance while maximizing therapeutic outcome [5,6]. Bacterial identification and MIC determinations are performed after the bacterial species has been isolated from a patient sample; obtaining this primary isolate requires an incubation period of 24–48 h [7]. The cost and size of these instruments restricts their use for point-of-care medicine and necessitates the establishment of centralized labs for high-throughput analysis of clinical samples

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call